Uhlmann D, Witzigmann H, Geissler F, Tannapfel A, Hauss J
Chirurgische Klinik II-Klinik für Abdominal-, Transplantations- und Gefässchirurgie, Universität Leipzig.
Zentralbl Chir. 2000;125(7):624-8.
For decision of adequate surgical therapy and comparison of results differentiation of hepatocellular carcinomas (HCC) in cirrhotic and noncirrhotic livers is important. Liver resection is the treatment of choice for HCC in noncirrhotic liver. Between 4/94 and 8/99 we treated 54 patients with hepatocellular carcinoma (HCC) by subtotal hepatic resection (n = 40) and orthotopic liver transplantation (n = 14). Overall 1- and 3-year survival rates of the resection group were 45 and 25% (median follow up: 3.5 years). One-year survival in the transplantation group was 72% (median follow up: 2.2 years). In patients with HCC in cirrhosis in UICC stage I to III the optimal therapy is a controversial issue. In these patients the results after liver resection are poor due to high operative mortality and recurrence (3-year recurrence-free survival: 30%). Regarding the literature, liver transplantation is the treatment of choice in small (< 3-5 cm, < or = 2 tumors) HCCs arising in cirrhosis with better outcome compared to resection. The data in the literature report 3-year-survival rates after liver transplantation of 60-80%. However, consequent patient selection is necessary for this treatment modality. Due to the limited donor resources liver transplantation is rarely justified in advanced tumors.
对于决定适当的手术治疗方法以及比较结果而言,区分肝硬化肝脏和非肝硬化肝脏中的肝细胞癌(HCC)很重要。肝切除术是治疗非肝硬化肝脏中HCC的首选方法。在1994年4月至1999年8月期间,我们对54例肝细胞癌(HCC)患者进行了次全肝切除术(n = 40)和原位肝移植术(n = 14)。切除组的总体1年和3年生存率分别为45%和25%(中位随访时间:3.5年)。移植组的1年生存率为72%(中位随访时间:2.2年)。对于国际抗癌联盟(UICC)I至III期肝硬化合并HCC的患者,最佳治疗方法是一个有争议的问题。在这些患者中,由于手术死亡率高和复发率高(3年无复发生存率:30%),肝切除术后的结果较差。根据文献,肝移植是治疗肝硬化中出现的小(<